PSMA PET Imaging Market Size and Share Analysis - Growth Trends and Forecasts (2025-2032)

Market Size and Trends

The PSMA PET Imaging market is estimated to be valued at USD 320 million in 2025 and is expected to reach USD 1.1 billion by 2032, growing at a compound annual growth rate (CAGR) of 18.7% from 2025 to 2032. This robust growth reflects increasing adoption of advanced imaging techniques in oncology, particularly for prostate cancer diagnosis and treatment monitoring, driven by technological advancements and expanding clinical applications worldwide.

Market trends indicate a significant shift towards precision medicine, with PSMA PET imaging being a critical tool for targeted cancer therapy. Rising awareness among healthcare providers, increasing reimbursement approvals, and ongoing research to enhance imaging accuracy are accelerating market expansion. Additionally, collaborations between imaging technology manufacturers and pharmaceutical companies are fostering integrated diagnostic solutions, further propelling market growth and innovation in this dynamic landscape.

Segmental Analysis:

By Imaging Modality: Dominance of PET/CT Driven by Clinical Integration and Diagnostic Accuracy

In terms of By Imaging Modality, PET/CT contributes the highest share of the PSMA PET Imaging market owing to its widespread clinical adoption, cost-effectiveness, and proven diagnostic accuracy. PET/CT combining functional imaging from PET with anatomical detail from CT has become the gold standard for detecting prostate cancer lesions, enabling clinicians to precisely localize tumors and assess metastatic spread. The integrated modality offers faster imaging times and better spatial resolution relative to standalone PET systems, which is critical in a disease where early and accurate detection directly influences treatment decisions. Moreover, the global availability of PET/CT scanners, supported by established reimbursement policies in many regions, further fuels its ongoing prominence.

In addition to its diagnostic advantages, PET/CT technology benefits from extensive clinician familiarity, which fosters confidence in interpreting imaging results and applying them to patient management. The accumulated clinical evidence demonstrating improved patient outcomes when utilizing PET/CT-based PSMA imaging bolsters its position as the preferred modality. Although newer modalities like PET/MRI are gaining recognition for superior soft-tissue contrast, PET/CT remains dominant due to its operational efficiency, lower maintenance costs, and broader infrastructure support in healthcare institutions. These factors collectively drive the sustained market leadership of PET/CT in PSMA PET imaging applications.

By Radiotracer Type: ^68Ga-PSMA Leads with Established Efficacy and Accessibility

By Radiotracer Type, ^68Ga-PSMA maintains the highest market share among all radiotracers used in PSMA PET Imaging, driven primarily by its well-documented efficacy in prostate cancer detection and relatively streamlined production processes. The radiotracer's strong affinity for prostate-specific membrane antigen (PSMA) receptors facilitates high-contrast tumor visualization, enabling clinicians to detect both primary and metastatic lesions with high sensitivity and specificity. Its versatility spans initial diagnosis, staging, and recurrence detection, making it invaluable across diverse clinical scenarios.

Operationally, ^68Ga-PSMA benefits from the fact that ^68Ga can be obtained from germanium-68/gallium-68 generators without requiring an on-site cyclotron, making it accessible to a broad range of medical centers, including those in regions with limited radiopharmaceutical infrastructure. This generator-based production reduces logistical complexities and lowers costs, enhancing adoption especially in markets where regulatory environments and supply chain challenges impact access to cyclotron-produced tracers. Furthermore, extensive clinical validation through numerous studies and regulatory approvals in multiple countries reinforces trust in ^68Ga-PSMA, driving its predominance among available PSMA-targeted radiotracers despite the emergence of newer fluorine-18 labeled agents.

By Application: Prostate Cancer Diagnosis Anchors Market through Early Detection Needs

By Application, Prostate Cancer Diagnosis accounts for the largest share of the PSMA PET Imaging market, underscored by the critical role this technology plays in improving early detection and accurate staging of prostate cancer. Early diagnosis directly affects treatment planning and prognosis, thus the demand for precise and non-invasive diagnostic tools such as PSMA PET imaging continues to rise. The ability of PSMA PET imaging to identify cancerous lesions at initial presentation with superior sensitivity compared to conventional imaging methods positions it as an indispensable tool in the urologist's arsenal.

Moreover, increasing awareness among clinicians regarding the diagnostic benefits of PSMA PET imaging is driving its inclusion in clinical guidelines and standard diagnostic pathways. This segment's growth is further propelled by the demographic trend of an aging male population, where prostate cancer incidence rates remain high. In parallel, healthcare providers are placing greater emphasis on personalized medicine, necessitating imaging modalities that can not only confirm diagnosis but also provide detailed insights into tumor burden and location, optimizing therapeutic decisions. These factors contribute to robust adoption for prostate cancer diagnosis relative to other applications such as recurrence detection or treatment monitoring, thereby establishing this role as the cornerstone of the PSMA PET imaging market landscape.

Regional Insights:

Dominating Region: North America

In North America, the dominance in the PSMA PET Imaging market is driven by a robust healthcare infrastructure, advanced technological adoption, and strong research and development capabilities. The presence of leading imaging and pharmaceutical companies such as Siemens Healthineers, GE Healthcare, and Progenics Pharmaceuticals bolsters innovation and wider availability of PSMA PET imaging agents. Additionally, supportive government policies including FDA approvals and reimbursement frameworks facilitate quicker clinical adoption. The well-established medical ecosystem, coupled with widespread awareness and screening programs for prostate cancer, further solidifies North America's leading position in this domain. Trade dynamics also favor this region due to streamlined regulatory processes and established distribution networks.

Fastest-Growing Region: Asia Pacific

Meanwhile, Asia Pacific exhibits the fastest growth in the PSMA PET Imaging market, driven by increasing healthcare expenditure, rising incidence of prostate cancer, and expanding diagnostic infrastructure. Countries like China, Japan, and India are witnessing enhanced government initiatives to modernize healthcare facilities and improve cancer diagnostics. The influx of global and regional players such as Bracco Diagnostics, Lantheus Holdings, and local innovators accelerates market penetration. Additionally, growing awareness and improving reimbursement policies contribute significantly. Trade dynamics in this region, with increasing cross-border partnerships and technology transfers, also help overcome previous market entry challenges, facilitating faster acceptance of PSMA PET imaging technologies.

PSMA PET Imaging Market Outlook for Key Countries

United States

The United States' PSMA PET imaging market benefits from significant investments in healthcare technology and extensive clinical research. Major players like Progenics (now part of Lantheus Holdings) and GE Healthcare have introduced novel imaging agents and PET scanners tailored for precision oncology. Stringent regulatory guidance from the FDA ensures high standards of safety and efficacy, fostering clinician trust. The country also has expansive cancer screening programs, driving early diagnosis and broad clinical adoption of PSMA PET imaging for prostate cancer management.

Germany

Germany continues to lead Europe's PSMA PET imaging market, supported by its advanced healthcare infrastructure and robust reimbursement systems. Companies such as Siemens Healthineers and Eckert & Ziegler AG play pivotal roles in deploying cutting-edge imaging technologies and radiopharmaceutical production. Strong collaborations between academic hospitals and industry players enhance clinical validation and adoption. Moreover, government support for innovation in nuclear medicine and streamlined regulatory processes create a conducive environment for rapid introduction of PSMA PET imaging services.

China

China's market is rapidly evolving due to growing awareness of prostate cancer and substantial government-led healthcare reforms, including expansion of nuclear medicine capabilities. Local companies alongside multinational corporations like Bracco Diagnostics have been instrumental in developing PSMA PET agents adapted for the local population. The country's strategic push to increase domestic manufacturing of radiopharmaceuticals and enhance distribution networks further supports rapid market growth. Increasing public and private sector partnerships accelerate clinical trials and the adoption of new diagnostic technologies.

Japan

Japan's PSMA PET imaging market is marked by strong technological advancement and early integration of new imaging modalities into clinical practice. Companies such as Shimadzu Corporation and FUJIFILM Toyama Chemical contribute significantly to the development and commercialization of novel imaging agents. The country's universal healthcare system and government incentives for cancer diagnostics aid widespread access. Research institutions and hospitals actively participate in validating PSMA PET imaging applications, supporting Japan's leadership in nuclear medicine innovation within Asia.

India

India's market is expanding due to increasing prostate cancer prevalence and growing investment in diagnostic imaging infrastructure. Domestic companies in collaboration with global firms are intensifying efforts to localize production of PSMA PET imaging agents to reduce costs and improve access. Government initiatives to enhance healthcare coverage and the growing private healthcare sector play a significant role in extending these advanced diagnostic services beyond metropolitan areas. Improving regulatory frameworks and rising clinician awareness further drive market growth in this emerging economy.

Market Report Scope

Market Segmentation

Imaging Modality Insights (Revenue, USD, 2020 - 2032)

• PET/CT
• PET/MRI
• Others

Radiotracer Type Insights (Revenue, USD, 2020 - 2032)

• ^68Ga-PSMA
• ^18F-DCFPyL
• ^18F-PSMA-1007
• Others

Application Insights (Revenue, USD, 2020 - 2032)

• Prostate Cancer Diagnosis
• Recurrence Detection
• Treatment Monitoring
• Emerging Applications
• Others

Regional Insights (Revenue, USD, 2020 - 2032)

• North America
• U.S.
• Canada
• Latin America
• Brazil
• Argentina
• Mexico
• Rest of Latin America
• Europe
• Germany
• U.K.
• Spain
• France
• Italy
• Russia
• Rest of Europe
• Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• ASEAN
• Rest of Asia Pacific
• Middle East
• GCC Countries
• Israel
• Rest of Middle East
• Africa
• South Africa
• North Africa
• Central Africa

Key Players Insights

• Siemens Healthineers
• GE Healthcare
• Bracco Imaging
• Lantheus Holdings, Inc.
• Invicro (Part of Konica Minolta)
• Telix Pharmaceuticals
• Curium Pharma
• Endocyte, Inc.
• Advanced Accelerator Applications (AAA)
• Ionetix Corporation
• Nuclear Diagnostic Products Limited
• Sumitomo Heavy Industries
• SOFIE Biosciences
• Cardinal Health
• Scintomics GmbH
• PETNET Solutions
• ABX Advanced Biochemical Compounds
• Jubilant Radiopharma